
Merck’s Clesrovimab Significantly Reduces RSV Incidence and Hospitalizations in Infants
Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, has shared positive results from its Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, an investigational monoclonal antibody designed to…












